Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism

被引:105
作者
Perabo, Luca
Goldnau, Daniela
White, Kathryn
Endell, Jan
Boucas, Jorge
Humme, Sibille
Work, Lorraine M.
Janicki, Hanna
Hallek, Michael
Baker, Andrew H.
Buening, Hildegard
机构
[1] Univ Munich, Genzentrum, Munich, Germany
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[3] Univ Glasgow, Cardiovasc Res Ctr, Div Cardiovasc & Med Sci, British Heart Fdn, Glasgow, Lanark, Scotland
[4] Univ Cologne, Ctr Mol Med, Cologne, Germany
[5] Natl Ctr Res & Environm, Gesellsch Strahlenforsch, Munich, Germany
关键词
D O I
10.1128/JVI.00076-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Adeno-associated virus type 2 (AAV-2) targeting vectors have been generated by insertion of ligand peptides into the viral capsid at amino acid position 587. This procedure ablates binding of heparan sulfate proteoglycan (HSPG), AAV-2's primary receptor, in some but not all mutants. Using an AAV-2 display library, we investigated molecular mechanisms responsible for this phenotype, demonstrating that peptides containing a net negative charge are prone to confer an HSPG nonbinding phenotype. Interestingly, in vivo studies correlated the inability to bind to HSPG with liver and spleen detargeting in mice after systemic application, suggesting several strategies to improve efficiency of AAV-2 retargeting to alternative tissues.
引用
收藏
页码:7265 / 7269
页数:5
相关论文
共 15 条
  • [1] Büning H, 2003, CURR OPIN MOL THER, V5, P367
  • [2] Receptor targeting of adeno-associated virus vectors
    Büning, H
    Ried, MU
    Perabo, L
    Gerner, FM
    Huttner, NA
    Enssle, J
    Hallek, M
    [J]. GENE THERAPY, 2003, 10 (14) : 1142 - 1151
  • [3] Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
    Girod, A
    Ried, M
    Wobus, C
    Lahm, H
    Leike, K
    Kleinschmidt, J
    Deléage, G
    Hallek, M
    [J]. NATURE MEDICINE, 1999, 5 (09) : 1052 - 1056
  • [4] Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids
    Grifman, M
    Trepel, M
    Speece, P
    Gilbert, LB
    Arap, W
    Pasqualini, R
    Weitzman, MD
    [J]. MOLECULAR THERAPY, 2001, 3 (06) : 964 - 975
  • [5] Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
    Kern, A
    Schmidt, K
    Leder, C
    Müller, OJ
    Wobus, CE
    Bettinger, K
    Von der Lieth, CW
    King, JA
    Kleinschmidt, JA
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (20) : 11072 - 11081
  • [6] Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells
    Nicklin, SA
    Buening, H
    Dishart, KL
    de Alwis, M
    Girod, A
    Hacker, U
    Thrasher, AJ
    Ali, RR
    Hallek, M
    Baker, AH
    [J]. MOLECULAR THERAPY, 2001, 4 (03) : 174 - 181
  • [7] Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding
    Opie, SR
    Warrington, KH
    Agbandje-McKenna, M
    Zolotukhin, S
    Muzyczka, N
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (12) : 6995 - 7006
  • [8] OWRK LM, 2006, MOL THER, V13, P683
  • [9] Combinatorial engineering of a gene therapy vector:: directed evolution of adeno-associated virus
    Perabo, L
    Endell, J
    King, S
    Lux, K
    Goldnau, D
    Hallek, M
    Büning, H
    [J]. JOURNAL OF GENE MEDICINE, 2006, 8 (02) : 155 - 162
  • [10] In vitro selection of viral vectors with modified tropism:: The adeno-associated virus display
    Perabo, L
    Büning, H
    Kofler, DM
    Ried, MU
    Girod, A
    Wendtner, CM
    Enssle, R
    Hallek, M
    [J]. MOLECULAR THERAPY, 2003, 8 (01) : 151 - 157